|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LRRC32 |
Gene summary for LRRC32 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LRRC32 | Gene ID | 2615 |
| Gene name | leucine rich repeat containing 32 | |
| Gene Alias | CPPRDD | |
| Cytomap | 11q13.5 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A0A024R5J7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2615 | LRRC32 | ATC12 | Human | Thyroid | ATC | 7.07e-11 | 2.38e-01 | 0.34 |
| 2615 | LRRC32 | ATC13 | Human | Thyroid | ATC | 7.17e-17 | 4.82e-01 | 0.34 |
| 2615 | LRRC32 | ATC2 | Human | Thyroid | ATC | 5.24e-13 | 1.01e+00 | 0.34 |
| 2615 | LRRC32 | ATC4 | Human | Thyroid | ATC | 9.63e-13 | 3.36e-01 | 0.34 |
| 2615 | LRRC32 | ATC5 | Human | Thyroid | ATC | 1.49e-24 | 5.07e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007155925 | Thyroid | ATC | response to transforming growth factor beta | 142/6293 | 256/18723 | 4.30e-13 | 1.94e-11 | 142 |
| GO:007156026 | Thyroid | ATC | cellular response to transforming growth factor beta stimulus | 137/6293 | 250/18723 | 3.69e-12 | 1.49e-10 | 137 |
| GO:000717924 | Thyroid | ATC | transforming growth factor beta receptor signaling pathway | 112/6293 | 198/18723 | 2.42e-11 | 8.44e-10 | 112 |
| GO:000717823 | Thyroid | ATC | transmembrane receptor protein serine/threonine kinase signaling pathway | 170/6293 | 355/18723 | 1.40e-08 | 2.87e-07 | 170 |
| GO:007160422 | Thyroid | ATC | transforming growth factor beta production | 25/6293 | 43/18723 | 8.24e-04 | 4.53e-03 | 25 |
| GO:007163422 | Thyroid | ATC | regulation of transforming growth factor beta production | 24/6293 | 41/18723 | 9.12e-04 | 4.92e-03 | 24 |
| GO:000716225 | Thyroid | ATC | negative regulation of cell adhesion | 127/6293 | 303/18723 | 1.45e-03 | 7.47e-03 | 127 |
| GO:00600211 | Thyroid | ATC | roof of mouth development | 42/6293 | 85/18723 | 1.83e-03 | 9.02e-03 | 42 |
| GO:00363631 | Thyroid | ATC | transforming growth factor beta activation | 8/6293 | 10/18723 | 3.60e-03 | 1.58e-02 | 8 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LRRC32 | SNV | Missense_Mutation | novel | c.610N>G | p.Leu204Val | p.L204V | Q14392 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| LRRC32 | SNV | Missense_Mutation | c.971N>G | p.Tyr324Cys | p.Y324C | Q14392 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| LRRC32 | SNV | Missense_Mutation | rs757982373 | c.442N>A | p.Ala148Thr | p.A148T | Q14392 | protein_coding | deleterious(0.02) | benign(0.327) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| LRRC32 | SNV | Missense_Mutation | c.1946N>C | p.Cys649Ser | p.C649S | Q14392 | protein_coding | deleterious(0) | possibly_damaging(0.795) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| LRRC32 | SNV | Missense_Mutation | rs370963014 | c.1070N>A | p.Arg357Gln | p.R357Q | Q14392 | protein_coding | tolerated(0.67) | benign(0) | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| LRRC32 | insertion | Frame_Shift_Ins | novel | c.1822_1823insCTGCACTT | p.Val608AlafsTer6 | p.V608Afs*6 | Q14392 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| LRRC32 | insertion | Frame_Shift_Ins | novel | c.1820_1821insCCCCCTTCCCG | p.Glu607AspfsTer8 | p.E607Dfs*8 | Q14392 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| LRRC32 | insertion | Frame_Shift_Ins | novel | c.365_366insAGAA | p.Leu123GlufsTer58 | p.L123Efs*58 | Q14392 | protein_coding | TCGA-A8-A099-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | ||
| LRRC32 | deletion | Frame_Shift_Del | c.940delN | p.Leu314PhefsTer5 | p.L314Ffs*5 | Q14392 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| LRRC32 | deletion | Frame_Shift_Del | c.993delN | p.Asp332ThrfsTer7 | p.D332Tfs*7 | Q14392 | protein_coding | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |